| Views | |
|---|---|
| 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years | 440 |
| July 2025 | August 2025 | September 2025 | October 2025 | November 2025 | December 2025 | January 2026 | |
|---|---|---|---|---|---|---|---|
| 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years | 5 | 25 | 175 | 31 | 27 | 28 | 46 |
| Views | |
|---|---|
| 2022_Rieger_etal.pdf | 84 |
